Scholar Rock Holding Corporation (NASDAQ:SRRK) Q3 2023 Earnings Call Transcript

Ted Myles: Yes. So I think there’s a couple of things again, back to the regulatory endpoints. And we’re going to begin the engagement with FDA and other agencies as we advance through IND and get more interaction with our clinical programs. But as an example, the functional measures, well, as you know, we’ve included functional measures in the SMA program, those were tailored specifically for the underlying disease. There’s other ways to measure the GLP strength and certain other measures that we could assess that would show that you’re preserving and maintaining motor function. So, that’s something to consider. There’s also measures that we can include the good look at quality of life measures. As you know, there are some significant associated GI effects with the current therapies.

It’s possible for our approach and what Mo showed, which I think is very intriguing is that we do have the potential to have some additive effect on weight loss. And by that activity, potentially getting the same effect on weight loss at lower doses. So, there’s really — I mean, we’ve got a lot of ideas around this. We’re really at the beginning of this effort — beginning of the effort of kind of mapping out the full clinical program to registration, but not at the beginning efforts of our deep thinking around myostatin and targeting this space, right? So, we’ve got a lot of good ideas, more to come, but I think we can do that. And then in terms of chronic therapy, that’s a very, very interesting question. As you know, I think there is a challenge with maintaining therapy on the current GLP-1 receptor agonist.

There is the potential for rapid rebound. If we take a look at muscle as a metabolic organ, which it is, the chances of restoring and preserving that could have some very interesting effects on maintaining the weight loss even at lower reduced GLP-1 therapy. And what we’re showing, at least from our perspective is that we certainly can give apitegromab chronically. Hope that data is really underscoring that. As I mentioned earlier, we have patients on four years. So, again, so a lot of questions to address in the clinical program, which is exciting for me, but I’m really excited by the fact that Mo and Mo’s team have 439 that they’ve moved since I joined the company to now talking about moving toward IND, really good progress from our research team.

Ernesto Rodriguez-Dumont: All right. Thank you. very helpful.

Operator: There are no further questions at this time. Mr. Jay Backstrom, I turn the call back over to you.

Jay Backstrom: Yes. So, listen, thank you. Thank you for your interest. Again, just to reinforce, I’m really delighted with the work our team has done, very pleased with our progress, and I really look forward to kind of driving through the rest of this year and really running into 2024, where we have some really major milestones. So, with that, we’ll close the call and once again, thank you.